Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00492089Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerSupportive Care